PSA Assessment in Male LUTS/BPE – CON
European Urology Focus · 2026-09 · 12 (4) · 631-632
DOI: 10.1016/j.euf.2026.03.008 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Urology Focus, 2026-09. Verfasst von François Hervé. Beteiligte Einrichtung: Department of Urology, ERN Accredited Centrum, Ghent University Hospital, Ghent, Belgium. Electronic address: Francois.herve@uzgent.be. Hauptthemen laut MEDLINE: Lower Urinary Tract Symptoms, Prostate-Specific Antigen, Prostatic Hyperplasia, Prostatic Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 3 Literaturangaben.
Abstract (Originalsprache)
In men presenting with lower urinary tract symptoms (LUTS), prostate-specific antigen (PSA) testing has limited clinical value and frequently leads to false positives and unnecessary investigations. LUTS are more often related to benign enlargement than cancer. Evaluation should focus on symptom assessment and functional causes rather than routine PSA-driven testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, ERN Accredited Centrum, Ghent University Hospital, Ghent, Belgium. Electronic address: Francois.herve@uzgent.be.
Zitieren
APA
Hervé, F. (2026). PSA Assessment in Male LUTS/BPE – CON. European Urology Focus, 12(4), 631-632. https://doi.org/10.1016/j.euf.2026.03.008
Vancouver
Hervé F. PSA Assessment in Male LUTS/BPE – CON. European Urology Focus. 2026;12(4):631-632. doi:10.1016/j.euf.2026.03.008
BibTeX
@article{Herv2026,
author = {Hervé, François},
title = {PSA Assessment in Male LUTS/BPE – CON},
journal = {European Urology Focus},
year = {2026},
volume = {12},
number = {4},
pages = {631--632},
doi = {10.1016/j.euf.2026.03.008}
}
EUVIMED